Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Sitagliptin 100 mg Relative to Januvia in Healthy Thai Volunteers Under Fasting Conditions
TCTR20210830005Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bio-innova. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20210830005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210830005.